Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory indolent non-Hodgkin lymphoma from the ongoing phase 1 CaDAnCe-101 study

Romain Guieze, Annamaria Frustaci, Chan Cheah, John Seymour, Dok Hyun Yoon, Irina Mocanu, Eric Mou, Pier Luigi Zinzani, Amitkumar Mehta, Constantine Tam, Judith Trotman, Yanan Zhang, Linlin Xu, Kunthel By, Amber Lussier, Shannon Fabre, Daniel Persky, Ranjana Advani

Blood (2025) 146 (Supplement 1): 3584.

https://doi.org/10.1182/blood-2025-3584

Published: 2025

Journal Articles

Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory Waldenström macroglobulinemia from the ongoing phase 1 CaDAnCe-101 study

Constantine Tam, Chan Cheah, John Seymour, Ricardo Parrondo, Mazyar Shadman, Damien Roos Weil, Stephan Stilgenbauer, Barbara Eichhorst, Herbert Eradat, Steven Treon, Yanan Zhang, Linlin Xu, Kunthel By, Shannon Fabre, Motohisa Takai, Amit Agarwal, Annamaria Frustaci

Blood (2025) 146 (Supplement 1): 3583.

https://doi.org/10.1182/blood-2025-3583

Published: 2025

Journal Articles

Molecular determinants of outcome in CLL patients treated on zanubrutinib registration trials

Inhye Ahn, Zunqiu Wang, Svitlana Tyekucheva, Kiyomi Mashima, Stacey Fernandes, Vanitha Ramakrishnan, Jessica Li, Linlin Xu, Rameen Beroukhim, Ignaty Leshchiner, Jennifer Brown

Blood (2025) 146 (Supplement 1): 2113.

https://doi.org/10.1182/blood-2025-2113

Published: 2025

Journal Articles

Updated efficacy and safety results of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) from the ongoing phase 1 CaDAnCe-101 study

Blood (2025) 146 (Supplement 1): 85.

https://doi.org/10.1182/blood-2025-85

Published: 2025

Journal Articles

Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory Richter transformation: Results from the ongoing phase 1 CaDAnCe-101 study

Meghan Thompson, Annamaria Frustaci, John Seymour, John Allan, Paolo Ghia, Olivier Dumas, Franck Morschhauser, Martin Dreyling, Stephan Stilgenbauer, Inhye Ahn, Romain Guieze, Yanan Zhang, Linlin Xu, Kunthel By, Shannon Fabre, Daniel Persky, Amit Agarwal, Carlo Visco

Blood (2025) 146 (Supplement 1): 3895.

https://doi.org/10.1182/blood-2025-3895

Published: 2025

Journal Articles

Evaluation of factors from established prognostic models in patients with chronic lymphocytic leukemia (CLL) treated with zanubrutinib: A post-hoc analysis of two phase 3 studies (SEQUOIA and ALPINE)

Jessica Li, Yang Shi, Linlin Xu, Xiaopeng Ma, Marcus Lefebure, Tommi Salmi, Teiko Sumiyoshi, Inhye Ahn

Blood (2025) 146 (Supplement 1): 5681.

https://doi.org/10.1182/blood-2025-5681

Published: 2025

Journal Articles

Zanubrutinib + venetoclax for treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), including patients with del(17p) and/or TP53 mutation and unmutated immunoglobulin heavy-chain variable status: 3-year results from SEQUOIA arm D

Mazyar Shadman, Talha Munir, Shuo Ma, Masa Lasica, Monica Tani, Tadeusz Robak, Ian Flinn, Jennifer R. Brown, Paolo Ghia, Emmanuelle Ferrant, Constantine Tam, Wojciech Janowski, Wojciech Jurczak, Linlin Xu, Tian Tian, Nataliya Kuptsova-Clarkson, Marcus Lefebure, Jamie Hirata, Alessandra Tedeschi

Blood (2025) 146 (Supplement 1): 5669.

https://doi.org/10.1182/blood-2025-5669

Published: 2025

Journal Articles

Bgb-16673, a Selective BTK Degrader, Exhibits Deeper Inhibition of Cancer Cell Signaling Pathways and Better Efficacy in MCL Models

Haitao Wang, Qiming Zhou, Lin Li, Weiwei Song, Shuang Peng, Xiangmei Chen, Linlin Xu, Teiko Sumiyoshi, Wei Jin, Zhirong Shen

Blood (2024) 144 (Supplement 1): 5833.

https://doi.org/10.1182/blood-2024-202909

Published: 2024

Journal Articles

Genomic Landscape of Ibrutinib- and/or Acalabrutinib-intolerant Patients with B-cell Malignancies Treated with Zanubrutinib in a Phase 2 Study

Blood (2023) 142 (Supplement 1): 6510.

https://doi.org/10.1182/blood-2023-180161

Published: 2023

Journal Articles

Broad Superiority of Zanubrutinib (Zanu) Over Bendamustine + Rituximab (BR) Across Multiple High-Risk Factors: Biomarker Subgroup Analysis in the Phase 3 SEQUOIA Study in Patients With Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) without del(17p)

Vanitha Ramakrishnan, Linlin Xu, Jason C. Paik, Carol Marimpietri, Eric Shen, Xiaoxi Dong, Jessica Li, Andreas Agathangelidis, Tian Tian, Aileen Cleary Cohen, Tadeusz Robak, Constantine S. Tam, Paolo Ghia, Andrew Rawstron, Jennifer R. Brown

Blood (2023) 142 (Supplement 1): 1902.

https://doi.org/10.1182/blood-2023-174543

Published: 2023

Journal Articles

Genomic Characterization of Patients in a Phase 2 Study of Zanubrutinib in BTK Inhibitor-Intolerant Patients with Relapsed/Refractory B-Cell Malignancies

Blood (2022) 140 (Supplement 1): 9269–9271.

https://doi.org/10.1182/blood-2022-167758

Published: 2022

Journal Articles

Phase 2 Study of Zanubrutinib in BTK Inhibitor-Intolerant Patients (Pts) with Relapsed/Refractory B-Cell Malignancies

Blood (2021) 138 (Supplement 1): 1410.

https://doi.org/10.1182/blood-2021-148544

Published: 2021

Journal Articles

Calvariae-Resident Osteomacs That Are Phenotypically and Functionally Distinct from Marrow-Derived Macrophages Interact with Megakaryocytes to Regulate Hematopoietic Stem Cell Function

Safa F Mohamad, Linlin Xu, Himes R Evan, Hao Wu, Marta Alvarez, Paul Childress, Korbin Davis, Melissa Kacena, Edward F. Srour, PhD

Blood (2016) 128 (22): 28.

https://doi.org/10.1182/blood.V128.22.28.28

Published: 2016

Journal Articles

CD166 Identifies Multiple Myeloma Cells That Preferentially Home to the Bone Marrow Microenvironment and Promote Disease Progression and Bone Lytic Disease

Linlin Xu, Christophe Machal, Hao Wu, Colin D Crean, Bradley Poteat, Angelo A. Cardoso, Helmut Hanenberg, Khalid Mohammad, Attaya Suvannasankha, Edward F Srour

Blood (2014) 124 (21): 174.

https://doi.org/10.1182/blood.V124.21.174.174

Published: 2014

Journal Articles

Role Of CD166 In Multiple Myeloma Cell Homing To The Bone Marrow Microenvironment and Disease Progression

Linlin Xu, Christophe Machal, Hao Wu, Bradley Poteat, Colin D. Crean, Angelo A. Cardoso, MD, PhD, John M Chirgwin, PhD, Helmut Hanenberg, MD, Khalid S. Mohammad, M.D. Ph.D., Attaya Suvannasankha, MD, Edward F Srour, PhD

Blood (2013) 122 (21): 3102.

https://doi.org/10.1182/blood.V122.21.3102.3102

Published: 2013

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory indolent non-Hodgkin lymphoma from the ongoing phase 1 CaDAnCe-101 study

Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory Waldenström macroglobulinemia from the ongoing phase 1 CaDAnCe-101 study

Molecular determinants of outcome in CLL patients treated on zanubrutinib registration trials

Updated efficacy and safety results of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) from the ongoing phase 1 CaDAnCe-101 study

Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory Richter transformation: Results from the ongoing phase 1 CaDAnCe-101 study

Evaluation of factors from established prognostic models in patients with chronic lymphocytic leukemia (CLL) treated with zanubrutinib: A post-hoc analysis of two phase 3 studies (SEQUOIA and ALPINE)

Zanubrutinib + venetoclax for treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), including patients with del(17p) and/or TP53 mutation and unmutated immunoglobulin heavy-chain variable status: 3-year results from SEQUOIA arm D

Bgb-16673, a Selective BTK Degrader, Exhibits Deeper Inhibition of Cancer Cell Signaling Pathways and Better Efficacy in MCL Models

Genomic Landscape of Ibrutinib- and/or Acalabrutinib-intolerant Patients with B-cell Malignancies Treated with Zanubrutinib in a Phase 2 Study

Broad Superiority of Zanubrutinib (Zanu) Over Bendamustine + Rituximab (BR) Across Multiple High-Risk Factors: Biomarker Subgroup Analysis in the Phase 3 SEQUOIA Study in Patients With Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) without del(17p)

Genomic Characterization of Patients in a Phase 2 Study of Zanubrutinib in BTK Inhibitor-Intolerant Patients with Relapsed/Refractory B-Cell Malignancies

Phase 2 Study of Zanubrutinib in BTK Inhibitor-Intolerant Patients (Pts) with Relapsed/Refractory B-Cell Malignancies

Calvariae-Resident Osteomacs That Are Phenotypically and Functionally Distinct from Marrow-Derived Macrophages Interact with Megakaryocytes to Regulate Hematopoietic Stem Cell Function

CD166 Identifies Multiple Myeloma Cells That Preferentially Home to the Bone Marrow Microenvironment and Promote Disease Progression and Bone Lytic Disease

Role Of CD166 In Multiple Myeloma Cell Homing To The Bone Marrow Microenvironment and Disease Progression

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only